Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs.

BMC infectious diseases - 13 Aug 2014

Sohn Hyung Rae, Min Bo Young, Song Joon Chang, Seong Mun Hyuk, Lee Sang Soo, Jang Eun Sun, Shin Cheol Min, Park Young Soo, Hwang Jin-Hyeok, Jeong Sook-Hyang, Kim Nayoung, Lee Dong Ho, Kim Jin-Wook

Abstract excerpt

BACKGROUND: The durability of off-treatment virologic responses has not been fully elucidated in chronic hepatitis B (CHB) patients who have previously achieved complete virologic suppression with nucleos(t)ide analog (NA) therapy. This study aimed to assess off-treatment virologic relapse rates and to characterize the outcomes of subsequent re-treatment in CHB patients who have discontinued oral NA following...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B e Antigens
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Guanine

Share to Hepatitis B, Chronic

Share to Lamivudine

Share to Multivariate Analysis

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 25125320
DOI: 10.1186/1471-2334-14-439
PMCID: PMC4148928

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs.PMID 25125320Read ↗

Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.Semantic proximity Read ↗

Compare HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate or tenofovir alafenamide fumarateSemantic proximity Read ↗

Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFNSemantic proximity Read ↗

Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis BSemantic proximity Read ↗

Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response.Semantic proximity Read ↗

Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment.Semantic proximity Read ↗

End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B.Semantic proximity Read ↗

Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?Semantic proximity Read ↗

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.Semantic proximity Read ↗

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.Semantic proximity Read ↗

Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.